RareCan
An organisation for the purpose of speeding up research and ultimately improving outcomes for people with rarer forms of cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Support Program | ||
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 14 % | 144 % |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
RareCan is a pioneering startup operating in the healthcare sector, specifically focusing on cancer research and clinical trials. The company provides a unique service that connects cancer patients with suitable clinical trials in the UK. RareCan's primary clients are cancer patients, particularly those with rare and aggressive forms of cancer such as triple-negative breast cancer and rhabdomyosarcoma. These patients often struggle to find relevant clinical trials due to the specialized nature of their conditions.
The market RareCan operates in is the clinical trials and cancer research sector, which is a critical component of the broader healthcare industry. This market is characterized by a high demand for innovative treatments and therapies, particularly for rare and hard-to-treat cancers.
RareCan's business model revolves around offering a comprehensive platform where patients can access a growing resource of information specific to their type of cancer and ongoing research in that area. The platform also provides a secure space for patients to store all documents and correspondence related to their cancer treatment. This service is designed to be user-friendly, requiring only a few minutes to set up, after which patients can utilize various tools, including the clinical trial finding service.
The company generates revenue through partnerships with pharmaceutical companies and research institutions that are conducting clinical trials. These organizations pay RareCan for access to a pool of potential trial participants who meet specific criteria. Additionally, RareCan may offer premium services or subscriptions to patients and healthcare providers for enhanced features and personalized support.
In summary, RareCan is a vital link between cancer patients and clinical trials, facilitating access to cutting-edge treatments and advancing cancer research.
Keywords: cancer research, clinical trials, patient matching, healthcare platform, rare cancers, triple-negative breast cancer, rhabdomyosarcoma, secure document storage, pharmaceutical partnerships, UK healthcare.